Think of strength as insurance. Maybe you don't care about how much you can lift, but you should want to know how to get stronger so you can live life to the fullest. Strong legs help you kick a ball ...

Super Micro Computer (SMCI) shares are down 31.0% over the last 21 trading days. This recent decline highlights worries regarding intensified competition in the AI server market and shrinking margins ...

Monday Night Football turns into a playoff litmus test this evening in Santa Clara as Brock Purdy’s San Francisco 49ers, fresh off a 41-22 statement over Arizona, welcome Bryce Young’s surging ...

Arista Networks (ANET) shares have decreased by 23.1% over the course of 21 trading days. This recent decline is due to concerns over weaker-than-expected margin guidance for Q4 2025 and skepticism ...

Prosecutors argued Combs deserves at least 11 years in prison. Sean “Diddy” Combs has been sentenced to 50 months in prison for his conviction on two prostitution-related offenses. He gets credit for ...

NuScale is making nuclear power relevant again. It's not the only company doing so, though. Its future is fuzzy simply because the sales-to-installation-to-operational time frame is so long, and it's ...

While advertising revenue is firmly in the driver's seat for growth, accounting for 94% of revenue in Q3, Reddit does have some opportunities from AI data licensing ...

Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company’s bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.

Once upon a time, Americans lined up in droves outside Walmarts and Targets, still full from Thanksgiving dinner, so they could be first in the door. Thankfully, these frenzied Black Friday ...

The growing demand for AI infrastructure creates clear opportunities for this tech industry stalwart. The demand for data center capacity, especially on servers capable of running artificial ...

Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike. But the biotech’s newest update has failed to garner ...